Low thrombogenicity of polyethylene glycol-grafted cellulose membranes does not influence heparin requirements in hemodialysis.
Heparin is the most commonly used anticoagulant for hemodialysis despite potentially serious side effects. Polyethylene glycol-grafted cellulose (PGC) membranes produce less activation of the coagulation cascade than cuprophane membranes. Anecdotally, we found some patients required a surprisingly low level of anticoagulation using these membranes. We compared the anticoagulant requirement of the PGC membrane with that of the cuprophane membrane in this randomized, prospective, crossover study. Sixty-three patients were randomized to treatment using either membrane, and heparin administration was progressively reduced to the lowest dose that prevented visible clotting in excess of that normally encountered. Patients underwent dialysis at this dose for 1 month, after which the heparin requirement and Kt/Vurea (1.162 x ln [urea pre/urea post]) were assessed. This process was then repeated for each patient using the other membrane, and the results were compared. Heparin administration during dialysis was reduced from a mean loading dose of 29.0 +/- 9.4 to 1.5 +/- 3.2 IU/kg for both membranes and a mean maintenance infusion of 14.0 +/- 6.7 to 0.77 +/- 1.6 IU/kg/h for both membranes (both P < 0.0001 v full anticoagulation; no difference between membranes). The Kt/Vurea was not significantly altered. Forty-six patients with PGC and 45 patients with cuprophane membranes underwent dialysis successfully without heparin during dialysis, and the other patients were using considerably reduced doses. Aspirin and warfarin had no effect on the heparin requirement. These results do not support the theory that PGC membranes have a lower anticoagulant requirement than cuprophane membranes; however, they suggest that dialysis can be performed successfully with much smaller anticoagulant doses than are currently in common use.
Wright
M J
MJ
Wellcome Wing, Leeds General Infirmary, Leeds, UK.
Woodrow
G
G
Umpleby
S
S
Hull
S
S
Brownjohn
A M
AM
Turney
J H
JH
D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D001672:Biocompatible Materials; D002482:Cellulose / Q000031:analogs & derivatives; D018592:Cross-Over Studies; D005260:Female; D006493:Heparin / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D011092:Polyethylene Glycols; D011446:Prospective Studies; D006435:Renal Dialysis; D013927:Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D001672:Biocompatible Materials; D008567:Membranes, Artificial; D011092:Polyethylene Glycols; D002482:Cellulose; D006493:Heparin; C009865:cuprammonium cellulose